myeloid cell pools. By extension, proliferation likely also drives disease progression. Hematopoietic cell proliferation, either remote in bone marrow and spleen or locally in plaque, may thus represent a therapeutic target.
Commonly, we rely on ex vivo cell cycle analysis to measure cellular proliferation. These assays have limited use for assessing proliferative tissue activity in patients with atherosclerosis because the tissues of interest are not readily available for biopsy. With few exceptions, we are currently limited to investigating circulating leukocytes. However, these cells do not proliferate, and monocyte numbers in blood may not faithfully reflect proliferation in plaque or hematopoietic organs. In a hypothetical scenario, plaque macrophage proliferation may be high, despite normal blood monocyte levels, resulting in inflamed vascular lesions that are prone to complications. An imaging biomarker that reports on proliferating cells would expand diagnostic capabilities to disease-relevant tissues and aid development of emerging cardiovascular immuno-modulatory drugs.
Imaging of cancer cells has explored the use of such a biomarker. 4 18 F-FLT, a positron emission tomography (PET) isotope-labeled thymidine analog, enriches in proliferating cells. Phosphorylation traps the agent intracellularly. 5 Thymine is one of the 4 bases needed for DNA replication that occurs before cell division. The small molecule PET agent 18 F-FLT has undergone clinical exploration for assessing proliferation, and its retention correlates with the histological cell cycle marker Ki67 in tumor cells, especially in brain, lung, and breast cancer. 6 In oncology, 18 F-FLT PET imaging has emerged as a promising strategy to monitor treatment response for some cancers that rely more on the DNA salvage pathway than on de novo thymidine synthesis. 5, 7, 8 The comparable proliferative rates of cancer cells and plaque macrophages and previous reports of 18 F-FLT uptake into hematopoietic tissues 5, 9, 10 led us to hypothesize that this agent could prove useful for imaging hematopoietic cells in cardiovascular disease. The frequent use of the thymidine analog bromodeoxyuridine (BrdU), an established tool in hematology to measure leukocyte and progenitor proliferation, further suggested that the thymidine analog 18 F-FLT may report on macrophage proliferation.
Here we show that atherosclerotic plaques in atherosclerotic apolipoprotein E knock out (ApoE −/− ) mice, rabbits, and patients accumulate 18 F-FLT. In accordance with the recently reported increase of macrophage proliferation in mature atherosclerotic lesions, 3 aortic 18 F-FLT retention correlates with the duration of an atherogenic diet in mice and with the Framingham Risk Score in patients. Macrophage-rich plaques with high 18 F-FDG signal show the highest 18 F-FLT uptake in atherosclerotic rabbit aortae. Hematopoietic organ 18 F-FLT uptake associates with hematopoietic activity: it increases in mice with atherosclerosis and after exposure to the Toll-like receptor (TLR) ligand lipopolysaccharide and decreases after injection of fluorouracil (5-FU), an antimetabolite drug that kills proliferating cancer cells and cycling hematopoietic stem and progenitor cells (HSPCs).
Methods
A detailed method section is available in the Online Data Supplement.
Mice
Female ApoE −/− and wild-type C57BL/6 mice (10-12 weeks old) were purchased from Jackson Laboratories. Atherosclerosis was induced by feeding high-cholesterol diet to ApoE −/− mice ranging from 10 to 28 weeks. In wild-type mice, modulation of hematopoietic progenitor cell proliferation in bone marrow and the spleen was induced by injecting lipopolysaccharide (10 μg/mouse IP on 3 and 1 days before imaging) and 5-FU (150 μg/g IP 12 hours before imaging 
Rabbits
Atherosclerosis was induced in 4 male New Zealand White rabbits by a combination of high-cholesterol diet and double balloon injury of the abdominal aorta.
11 Rabbits were imaged 6 months after diet initiation. Four control rabbits received normal diet. All procedures in rabbits were approved by the IACUC at Mount Sinai Hospital, New York City, NY.
Small Animal PET-Computed Tomography Imaging and Image Analysis

18
F-FLT was injected via tail vein 120 minutes before in vivo imaging with an average dose of 22.44±1.07 MBq. This dose and imaging time point were chosen based on published biodistribution data and because mice have high circulating thymidine levels that compete with the PET agent for uptake into proliferating cells. 7 Mice were imaged with an Inveon small-animal PET-computed tomography (CT) scanner (Siemens Medical Solutions, Inc, Malvern, PA). CT was performed before PET, acquiring 360 cone beam projections (source power 80 keV and current 500 μA). During CT acquisition, iodine contrast was infused via the tail vein at a rate of 35 μL/min. For quantitative analysis, 1 to 3 regions of interest were drawn manually in the aortic root, the spleen, and the spine of each animal, guided by CT images. After in vivo imaging, mice were euthanized and the direct γ counting was performed on the aortic root, the spleen, and a femur. The data are presented as percent injected dose per gram of tissue (%IDGT).
Rabbit Imaging
Animals were subjected to high-resolution 3-dimensional T2-weighted magnetic resonance imaging with a 7-tesla scanner (Magnetom 7T, Siemens Healthcare, Erlangen, Germany). To establish 18 . Approximately 15 minutes before imaging, rabbits were anesthetized using an injection of ketamine (35 mg/kg) and xylazine (5 mg/kg), and the bladder was emptied. Anesthesia was maintained during imaging using 1% isofluorane breathing anesthesia. PET/CT was performed using a clinical scanner (Siemens Biograph mCT, PET/CT, Siemens, Erlangen, Germany), in 3D mode, using 1 bed position, for 60 minutes. Images were acquired from the thoracic aorta down to the iliac bifurcation. A noncontrast enhanced CT was also performed for attenuation correction of the PET images and to identify the aorta during image analysis. 
Human
Mice
We began by exploring the uptake of 18 F-FLT in the thoracic aorta of ApoE −/− mice that consumed a high-fat diet. In these mice, the aortic root harbors plaques inhabited by proliferating macrophages. ApoE −/− but not wild-type mice had areas of increased PET signal that colocalized with the aortic root and the ascending aorta on CT angiography ( Figure 1A ). The PET-derived SUV measured in the aortic root in ApoE −/− mice significantly exceeded that in wild-type mice (wild-type controls versus ApoE −/− mice, 0.053±0.010 versus 0.169±0.013, P<0.05; Figure 1B ). We further observed signal in the thoracic vertebrae and the sternum in both cohorts, a finding that stimulated further exploration. Ex vivo data obtained by scintillation counting (%IDGT, wild-type controls versus ApoE −/− mice, 0.214±0.015 versus 0.376±0.037, P<0.05; Figure 1C ) and autoradiography ( Figure 1D ) confirmed higher activity in the aortae excised from ApoE −/− mice, and peak signal colocalized with Oil Red O stained atherosclerotic lesions. As reported previously, the aortic root contained numerous Ki67 + CD68 + macrophages ( Figure 1E ). 3 Macrophages contributed 73.5±2.8% of all proliferating Ki67 + cells in the aortic wall. We found significantly less proliferating endothelial cells, smooth muscle cells, and T lymphocytes in the atherosclerotic aortic root ( Figure 1E and 1F). The fraction of proliferating macrophages was quantified in digested whole aortae by flow cytometric analysis. Significantly more macrophages were in the active S/G2/M phases of the cell cycle in aortae harvested from ApoE −/− mice ( Figure 1G and 1H). Previously, we had described that local macrophage proliferation increases in mature atherosclerotic lesions. 3 In line with these data, we found a positive correlation between scintillation counts in aortae of mice injected with 18 F-FLT and the duration of the atherogenic diet ( Figure  1I ). In ApoE −/− mice that received 5-FU, which reduces cell proliferation, 3 uptake of 18 F-FLT in the aortic root was reduced ( Figure 2D and 2E). Of note, 18 F-FLT and BrdU are both thymidine analogs and were injected at the same time. These data suggest that 18 F-FLT signal in atherosclerotic mouse aortae mostly reflects local proliferation of macrophages, but other cells, such as endothelial or smooth muscle cells, may also contribute to the PET signal to a smaller degree. 
The thymidine analog 18 F-FLT enriches in organs with high proliferative rates, including the hematopoietic bone marrow. 5 Intrigued by our observation of high PET signal in the sternum and vertebrae and because the hematopoietic system supplies monocytes to inflamed atherosclerotic plaque, we systematically compared 18 F-FLT uptake in the bone marrow and spleen of ApoE −/− mice to wild-type controls ( Figure 3A ). In vivo SUV in bone marrow rose in mice with atherosclerosis (wild-type controls versus ApoE −/− mice, 0.132±0.013 versus 0.276±0.020, P<0.05; Figure 3B ) Figure   3C ). These observations could result from higher thymidine uptake, DNA synthesis, and proliferation of HSPC. Indeed, flow cytometric analysis paralleled the in vivo PET data Figure 3H ) revealed higher 18 F-FLT uptake. As in the marrow, the higher tracer uptake paralleled increased cycling of LSK in the spleen of ApoE −/− mice ( Figure 3I and 3J). These data indicate that 18 F-FLT reflects increased hematopoietic activity in the marrow and spleen of mice with atherosclerosis, in accordance with the previous description of increased bone marrow hematopoiesis in atherosclerotic mice 12 and the reactivation of extramedullary, that is, splenic hematopoiesis in atherosclerosis. Hematopoiesis provides billions of blood cells every day and increases the production of leukocytes according to numerous stimuli. For instance, HSPCs express TLR4 on their surface, and TLR4 ligation increases proliferation, differentiation, and output of mature cells, including monocytes. 14 We therefore hypothesized that the changes observed in hematopoietic organs of mice with atherosclerosis could be reproduced with lipopolysaccharide, a bacterial TLR4 ligand that strongly stimulates hematopoiesis.
14 Wild-type mice that received lipopolysaccharide showed increased bone marrow uptake of 18 F-FLT ( Figure 4A and 4B) that paralleled results of ex vivo scintillation counting ( Figure 4C ). In accordance with the observed uptake of 18 F-FLT, a higher fraction of LSK was in the active cell cycle phase after lipopolysaccharide injection ( Figure 4D and 4E). TLR4 ligands induce HSPC migration from the bone marrow to the spleen, where the cells seed extramedullary niches. Indeed, splenic uptake of 18 F-FLT was increased, as observed by in vivo imaging ( Figure 4F and 4G) and ex vivo scintillation counting ( Figure 4H ). In parallel, the number of cycling LSK increased dramatically in spleens of mice that received lipopolysaccharide ( Figure 4I and 4J) .
Dampening of Hematopoiesis With 5-FU Decreases
18
F-FLT Signal
Next we explored whether 18 F-FLT signal might also monitor a decrease of hematopoietic activity. To test this hypothesis, we treated wild-type mice with 5-FU, a clinical drug that is frequently used in hematology research to ablate cycling stem cells. Previously, 5-FU reduced 18 F-FLT signal in tumorbearing mice. 15 Treatment with 5-FU reduced bone marrow Figure 5A and 5B) and ex vivo ( Figure 5C ). As expected, 5-FU decreased proliferation of bone marrow LSK ( Figure 5D and 5E). The spleen showed a similar pattern: 5-FU treatment reduced 
In Vitro 18 F-FLT Uptake
To better understand cellular 18 F-FLT uptake, we pursued in vitro incubation of the tracer in primary murine cells. Peritoneal macrophages were isolated by negative magnetic bead selection and either treated with 5-FU or not. Scintillation counting revealed that macrophages that were not treated with 5-FU showed higher uptake of the PET tracer ( Figure 6A ). Fluorescence-activated cell sorter analysis of these samples reported decreased staining for the proliferation marker Ki67 ( Figure 6B and 6C) . Further, we used positive magnetic bead selection of murine bone marrow to enrich for c-kit + progenitor cells and Ly6G + neutrophils. Incubation of these cells with 18 F-FLT was followed by scintillation counting. We detected higher uptake of 18 F-FLT into c-kit + cells ( Figure 6D ), and flow cytometry documented their higher proliferative activity when compared with Ly-G + cells ( Figure 6E and 6F). Of note, these data do not confer specificity of the PET tracer to progenitor cells but rather indicate that proliferating cells, including c-kit + progenitor cells, have a higher propensity to take up the imaging agent.
F-FLT PET in Rabbits With Atherosclerosis
To study 18 F-FLT plaque uptake in a different species, we subjected 4 rabbits with atherosclerosis and balloon injury and 4 control rabbits without atherosclerosis to PET/CT imaging. Magnetic resonance imaging confirmed that the treatment induced robust atherosclerotic lesions in the infrarenal aorta ( Figure 7A ). Rabbits first underwent 18 F-FDG PET imaging, which showed a heterogeneous pattern of inflammatory activity ( Figure 7B ). As expected, the 18 F-FDG signal was significantly higher in the aortic segments of rabbits with atherosclerosis (SUV mean controls, 0.20±0.002; atherosclerosis cohort, 0.58±0.02, P<0.0001). Immunohistochemistry of antirabbit macrophage (RAM11) staining demonstrated abundant macrophages in the atherosclerosis of these rabbits ( Figure 7C ). Previous correlation of 18 F-FDG to histology in atherosclerotic rabbits 16 and in humans 17 showed that 18 F-FDG PET signal increases with higher macrophage plaque burden. Within 48 hours of the 18 F-FDG PET, rabbits were rescanned after injection of 18 F-FLT, enabling a comparison of both PET agents. Pharmacokinetic experiments revealed a blood half-life of 20.36±3.54 minutes for 18 F-FLT in atherosclerotic rabbits and an optimal injection-imaging sequence of 200 minutes. The aortic 18 F-FLT signal was higher in rabbits with atherosclerosis when compared with control rabbits without atherosclerosis ( Figure 7D and 7E) . We used the 18 F-FDG data to classify 3 aortic regions in rabbits with atherosclerosis: low (SUV<0.4), intermediate (0.4-0.6), and high-grade inflammation (SUV>0.6). The vascular territories that were classified as high-grade inflammation showed the highest 18 F-FLT signal ( Figure 7F and 7G) . Linear regression analysis in aortic segments of rabbits with atherosclerosis revealed that 18 F-FLT and 18 F-FDG signal were weakly positively correlated ( Figure 7H ), whereas no correlation was detected in control rabbits.
F-FLT PET in Humans With Atherosclerosis
To assess the potential of 18 F-FLT for PET imaging of proliferation in human atherosclerotic plaque, we performed a retrospective analysis of 10 patients with high risk of cardiovascular disease (atherosclerosis group) and 10 patients with a low cardiovascular risk profile (control group) that were originally imaged because of malignant disease and stratified by Framingham Scoring (Table) . We found that patients with high cardiovascular risk showed intense calcification, indicative of atherosclerotic lesions ( Figure 8A ). Patients had undergone both, 18 F-FDG and 18 F-FLT PET imaging ( Figure 8B and 8C) . Analysis of the ascending aorta ( Figure 8D-8G ) and the carotid artery ( Figure 8H-8K) showed increased vascular uptake of both PET agents in the individuals with high cardiovascular risk. As observed in rabbits, linear regression analysis in aortic segments showed a weak positive correlation between 18 F-FLT and 18 F-FDG uptake (Figure 8 L) .
Discussion
Why are we interested in imaging macrophage proliferation? In inflamed tissue, these cells have a short to intermediate life span, ranging from hours to weeks. In mice with atherosclerosis, the entire plaque macrophage population turns over in 1 month. 3 Provision of mononuclear phagocytes influences atherosclerosis progression and plaque characteristics. 2 Depleting macrophages and monocytes or inhibiting their recruitment to plaque reproducibly diminishes atherosclerosis in animals. Although several interventions may influence macrophage proliferation, noninvasive imaging reporting on this process could markedly facilitate drug development by informing dose selection and providing an early biomarker of effective targeting. Oncology and neurodegenerative research adopted such companion-imaging strategies for rapid, noninvasive feedback on the targeted pathway or molecule in small numbers of patients. Such information would inform study design and the triage of candidates to advance into large-scale trials, enabling a nimbler drug development strategy. 18 Tissue-resident macrophages proliferate everywhere. 19 All major organ systems, including the vasculature, heart, and brain, host a network of noninflammatory stromal macrophages. These cells have as of yet unclear functions, but they may promote tissue homeostasis, defense, and regeneration. 20 We found that most healthy organs had low 18 F-FLT baseline uptake, likely reflecting the low proliferative rate of stromal cells and tissue macrophages. The bone marrow, intestine, kidney, and liver furnish notable exceptions, as reported previously. 5 These organs have high baseline proliferative activity or participate in the excretion of 18 F-FLT. HSPCs increase proliferative activity in the bone marrow in atherosclerosis after myocardial infarction and after stroke. 12, 21, 22 Circulating danger signals may also directly alert HSPCs to remote organ ischemic or other injury. 2 Compromised reverse cholesterol transport induces increased HSPC activity, linking metabolism to monocyte production. 12 Monocyte numbers in blood then rise with progressing hyperlipidemia 23 and associate with poor prognosis.
2 Cardiovascular disease also reactivates splenic leukocyte production. Gradually in mice with atherosclerosis, 13 and rapidly after ischemia, 22 HSPCs seed the splenic red pulp and expand monocyte production. Splenic HSPC retention relies on vascular cell adhesion molecule-1 expression by CD169 + macrophages. 24 GM-CSF, M-CSF, and interleukin-3 mediate splenic myelopoiesis. 13, 24 Indeed, increased splenic and bone marrow 18 F-FDG uptake associates with higher cardiovascular event rates in patients. 25 The decisive contribution of local proliferation to the enlarged macrophage pool in atherosclerotic lesions engendered interest in this process. 3 In mice with mature lesions, genetic deficiency of scavenger receptor A reduces incorporation of the thymidine analog BrdU into lesional macrophages. These pathways may have contributed to the increased 18 F-FLT PET signal observed in the present study, and their exploration as therapeutic targets will benefit from an imaging biomarker, such as 18 F-FLT PET. Rabbits with atherosclerosis displayed increased 18 F-FLT signal in vascular territories with high 18 F-FDG uptake. However, the correlation between both tracers in aortic segments of atherosclerotic rabbits and patients was weak. 18 F-FDG is trapped inside cells with high glucose uptake and correlates with macrophage number in the atherosclerotic plaque in rabbits and humans. 16, 17 Macrophage accumulation depends on increased proliferation and on monocyte recruitment. The observation of matching tracer uptake in some aortic segments supports that 18 F-FLT enriches in plaques with high macrophage proliferation because cell growth and proliferation are energy-intensive processes. In distinction to 18 F-FLT, 18 F-FDG is not specific for proliferating cells. Thus, some aortic segments high in 18 F-FDG may have a high glucose uptake but low proliferating rates. Taken together, 18 F-FLT may be a useful to study macrophage supply while reducing proliferation of hematopoietic cells. Myocardial uptake of 18 F-FDG can interfere with coronary artery imaging, a limitation that does not occur with 18 F-FLT.
As indicated by its use for imaging proliferating cancer cells, 18 F-FLT is not specific for macrophages or hematopoietic progenitor cells. Parenchymal cells that proliferate in plaque or hematopoietic organs may contribute to the observed signal, including endothelial and smooth muscle cells. This is a significant limitation of 18 F-FLT PET imaging, which is perhaps counterbalanced by its clinical availability. Our histological data imply, however, that most Ki67 + plaque cells were macrophages. A strategy to increase specificity for macrophages could rely on multimodal PET/ magnetic resonance imaging, in which 18 F-FLT PET could be combined with iron oxide macrophage magnetic resonance imaging.
18 F-FLT signal colocalization with T2* MR signal decrease may confer increased cellular specificity. 18 F-FLT has not shown adverse effects in clinical imaging trials, paving the way for a prospective trial that correlates 18 F-FLT signal in plaque and hematopoietic organs with clinical outcome. What Is Known?
Sources of Funding
• Macrophages promote disease progression in atherosclerosis.
• The turnover of macrophages is rapid, making it interesting to study their supply.
• Macrophages derive either from monocytes, which are progeny of hematopoietic stem cells in the marrow and spleen, or, especially in mature plaque, from local proliferation.
What New Information Does This Article Contribute?
F-FLT, a thymidine analog that avidly incorporates into proliferating cells, enriches in atherosclerotic plaque of mice, rabbits, and human patients.
• Although other stromal cells contribute, the majority of proliferating cells in atherosclerotic lesions are macrophages. • 18 F-FLT positron emission tomography (PET)-CT imaging reports increased activity in the hematopoietic organs of mice with atherosclerosis.
• 18 F-FLT plaque uptake increases with the duration of diet exposure in apolipoprotein E knock out mice.
• Originally developed for imaging proliferation in malignant disease, this PET imaging method may allow monitoring the expansion of hematopoietic cells in the setting of atherogenesis.
Myeloid cells are key protagonists in the progression of atherosclerotic disease. In inflammation, their life span is considerably shortened, which motivated the field's recently emerging interest in the production of these cells. The small molecule positron emission tomography tracer 18 F-FLT is an analog to the DNA building block thymidine. Just like bromodeoxyuridine, another thymidine analog used to measure cell proliferation, it incorporates into cells that are actively cycling. Our data suggest that 18 F-FLT positron emission tomography-CT imaging may be a clinically available method to study hematopoietic activity in patients with atherosclerosis. This could be of particular value in testing novel antiatherosclerotic therapies designed to diminish macrophage infiltration into inflammatory atherosclerotic plaques.
Small animal positron emission tomography (PET)-computed tomography (CT) imaging and image analysis. 18 F-FLT was injected via tail vein 120 min before in vivo imaging with an average dose of 22.24±1.07MBq. This dose and imaging time point were chosen based on published biodistribution data and because mice have high circulating thymidine levels that compete with the PET agent for uptake into proliferating cells 4 . Because FLT has a relatively long retention in blood, mice were hydrated by giving 400µl PBS i.p. prior to FLT injection. In addition, 4.5mg/Kg Furosemide (Hospira Inc., Lake Forest, IL) was given i.p. after FLT injection. Mice were imaged with an Inveon small-animal PET-CT scanner (Siemens Medical Solutions, Inc., Malvern, Pennsylvania). CT was performed prior to PET, acquiring 360 cone beam projections (source power 80 keV and current 500 µA). The CT contrast agent Isovue370 was infused via tail vein at 50µl/min. Static PET was acquired for 45 min. During image acquisition, mice were anesthetized by using 1-2% isoflurane mixed with oxygen. A high-resolution Fourier rebinning algorithm and the ordered subset expectation maximization (OSEM) method were used for image reconstruction. Image voxel sizes are 0.11 x 0.11 x 0.11 mm and 0.83 x 0.83x 0.83 mm for CT and PET, respectively. For quantitative analysis, regions of interest (ROIs) were drawn manually in the aortic root, the spleen and the spine of each animal, guided by CT images. Standardized uptake values (SUV) were defined as the ratio of the tissue radioactivity concentration c(t) (Bq/g) at the time point of imaging t, and the injected activity (in Bq, decay corrected for the time point of imaging t) divided by the body weight (g). After in vivo imaging, mice were sacrificed and the direct γ counting was performed on the aortic root, the spleen and a femur using a gamma counter (1480 Wizard 3", PerkinElmer, Boston, Mass). The data are presented as percent injected dose per gram of tissue (%IDGT).
Autoradiography and oil red O staining of aortae. After 18 F-FLT injections, aortae from both wild-type and ApoE -/-mice were excised and exposed for autoradiography on the PhosphorImager (SI, Molecular Dynamics, Sunnyvale, Calif) for 24 hours. Subsequently, aortae were briefly incubated with 60% 2-propanol and stained with 0.5% Oil Red O solution for 15 min at room temperature. After rinsing in 60% 2-propanol, aortae were washed repeatedly in PBS. Photographs of aortae were taken by using a digital camera with a micron lens (Sony).
Rabbit imaging. Animals were subjected to high-resolution 3 dimensional T2-weighted magnetic resonance imaging (MRI) with a 7-tesla scanner ( Magnetom 7T, Siemens Healthcare, Erlangen, Germany). To establish 18 F-FLT's pharmacokinetics, animals were injected with ~111MBq and blood was drawn at 2, 5, 15, 30, 60, 120 and 240 min. Radioactivity was measured by a Wizard 2470 Perkin Elmer automatic gamma counter. Values were calculated as %IDGT. All 8 rabbits (average weight 3.47 +/-0.37 Kg) underwent two PET/CT scans, on 2 different days. The first PET/CT was performed after injection of 18 F-FDG, while the second PET/CT was performed after the injection of 18 F-FLT. For both imaging sessions rabbits were fasted for 4 hours before the isotope injection (water was provided at libitum). Before injection rabbits were appropriately restrained, and the isotope was injected through a catheter placed in a marginal ear vein. The average injected dose of FDG was 190.3 +/-9. . Approximately 15 minutes before imaging, rabbits were anesthetized using an injection of ketamine (35mg/kg) and xylazine (5mg/kg), and the bladder was emptied. Anesthesia was maintained during imaging using 1% isofluorane breathing anesthesia. PET/CT was performed using a clinical scanner (Siemens Biograph mCT, PET/CT, Siemens, Erlangen, Germany), in 3D mode, using one bed position, for 60 minutes. Images were acquired from the thoracic aorta, down to the iliac bifurcation. A non contrast enhanced CT was also performed for attenuation correction of the PET images, and to identify the aorta during image analysis.
Following acquisition, images were transferred to a workstation for image analysis. Both PET and CT images were under-sampled to a resolution of 3 mm in the longitudinal direction, with respect to the scanner reconstruction (1 mm). PET images were reconstructed using an OSEM +PSF+TOF algorithm (Ordered Subset Expectation Maximization with Point Spread Function and Time Of Flight), using 3 iterations and 21 subsets. The iliac and renal arteries were identified on CT images and used as anatomical landmarks. On axial CT slices, circular ROIs were drawn to encompass the aorta, from the left renal artery to the iliac bifurcation using Osirix (http://www.osirix-viewer.com). Care was taken to exclude slices where aortic uptake was contaminated by bowel or bladder uptake. ROIs were then copied to the co-registered PET images and isotope concentration values (Bq/ml) were converted to SUV. Both mean and maximum SUV within aortic ROIs was calculated. Following, FDG SUV mean and maximum values were divided into 3 groups using a custom made Matlab program (www.mathworks.com). For SUV mean the groups were: 1) SUV between 0 and 0.4; 2) SUV between 0.4 and 0.6; SUV higher than 0.6. For SUV maximum the groups were: 1) SUV between 0 and 0.6; 2) SUV between 0.6 and 0.9; 3) SUV higher than 0.9. FLT slices corresponding to these FDG cut-offs were identified. FDG and FLT SUV mean and maximum values were correlated slice-by-slice starting from the left renal artery, identified in both scans as anatomical landmark.
Flow cytometry. Aortae of ApoE -/-and wild-type control mice were digested in enzyme mixture 5 . Single-cell suspensions of the digested aorta were stained with the following antibodies against
